<qa>  What was the goal of the multicentric Phase III study?The objective of this multicentric Phase III study is to confirm the results of the phase I-II study Dreno B Al. Cancer Immunol Immunother 2002; 51: 539-456 which demonstrated the preventive effect of a treatment by TIL Tumor Infiltrating Lymphocytes combined with IL2 Interleukin 2; low dose injected subcutaneously on the metastatic relapse in the stage III melanoma patients with only one invaded lymphnode. 